What are the five major groups of pulmonary hypertension and their underlying pathophysiology?

Pulmonary Hypertension Classification

Overview and Definition

Pulmonary hypertension is classified into five major clinical groups based on shared pathophysiology, hemodynamic characteristics, and treatment strategies, with the fundamental diagnostic threshold being a mean pulmonary artery pressure ≥25 mmHg at rest. 1

The classification system groups conditions that share similar clinical presentations, pathological findings, and therapeutic approaches, allowing clinicians to systematically approach diagnosis and treatment. 1 This framework evolved from the 2003 Venice classification and was updated at the 2015 ESC/ERS guidelines to reflect advances in understanding disease mechanisms. 1

---

Hemodynamic Definitions

Before discussing the five groups, understanding the hemodynamic criteria is essential:

• Pulmonary hypertension (all groups): Mean PAP ≥25 mmHg at rest 1
• Pre-capillary PH: Mean PAP ≥25 mmHg AND pulmonary artery wedge pressure (PAWP) ≤15 mmHg 1
• Post-capillary PH: Mean PAP ≥25 mmHg AND PAWP >15 mmHg 1
• Pulmonary vascular resistance (PVR) >3 Wood units distinguishes true pulmonary arterial hypertension from other forms of pre-capillary PH 1

---

Group 1: Pulmonary Arterial Hypertension (PAH)

Hemodynamic Profile

Group 1 is defined by pre-capillary hemodynamics: mean PAP ≥25 mmHg, PAWP ≤15 mmHg, and PVR >3 Wood units. 1

Pathophysiology

The underlying mechanism involves remodeling of small pulmonary arteries (<500 μm diameter), leading to progressive vascular obstruction and increased pulmonary vascular resistance. 2 This results from endothelial dysfunction affecting three key pathways: nitric oxide, endothelin-1, and prostacyclin. 2

Subgroups

Idiopathic PAH (IPAH):

• Occurs without identifiable trigger or family history 1
• Replaced the older term "primary pulmonary hypertension" 1
• Shows female predominance 3

Heritable PAH (HPAH):

• Most commonly linked to BMPR2 (bone morphogenetic protein receptor type 2) mutations 1
• Rarer mutations include ALK1, endoglin, EIF2AK4, and other genes 1
• Follows autosomal-dominant inheritance with incomplete penetrance 4

Drug- and toxin-induced PAH:

• Definite causative agents include appetite suppressants (aminorex, fenfluramine, dexfenfluramine) and dasatinib 1
• Discontinuation may lead to clinical improvement 5

Associated PAH (APAH):

• Connective tissue disease: Systemic sclerosis carries the highest risk and worst prognosis 1
• Congenital heart disease: Systemic-to-pulmonary shunts (atrial septal defect, ventricular septal defect, patent ductus arteriosus) can progress to Eisenmenger syndrome when PVR exceeds systemic vascular resistance 1
• Portal hypertension: Risk increases with worsening hepatic function 1
• HIV infection: Affects approximately 0.5% of infected individuals, independent of CD4 count 1
• Schistosomiasis: Major cause in endemic regions 1

Pulmonary veno-occlusive disease (PVOD) and pulmonary capillary hemangiomatosis (PCH):

• Distinct entities with prominent venous or capillary involvement 1
• May be idiopathic, heritable (EIF2AK4 mutations), or secondary to drugs, radiation, connective tissue disease, or HIV 1
• Classified as Group 1′ in the updated classification 1

Persistent pulmonary hypertension of the newborn (PPHN):

• Heterogeneous group subcategorized as Group 1″ 1

---

Group 2: Pulmonary Hypertension Due to Left Heart Disease

Hemodynamic Profile

Group 2 is defined by post-capillary hemodynamics: mean PAP ≥25 mmHg AND PAWP >15 mmHg. 1

Epidemiology and Pathophysiology

This is the most common form of pulmonary hypertension, affecting up to 60% of patients with severe left ventricular systolic dysfunction and up to 70% of those with heart failure with preserved ejection fraction. 1

The mechanism involves backward transmission of elevated left ventricular end-diastolic pressure through the left atrium into pulmonary veins, raising PAWP and causing pulmonary venous congestion. 1 In some patients, chronic venous congestion triggers superimposed pulmonary arterial vasoconstriction and remodeling, creating a combined pre- and post-capillary phenotype identified by a transpulmonary gradient >12 mmHg or PVR >3 Wood units. 1

Etiologies

• Left ventricular systolic dysfunction of any cause 1
• Left ventricular diastolic dysfunction, commonly from chronic hypertension causing LV hypertrophy 1
• Valvular disease: virtually all patients with severe symptomatic mitral disease and up to 65% with symptomatic aortic stenosis develop PH 1
• Congenital or acquired left heart inflow/outflow obstruction and congenital cardiomyopathies 1
• Congenital or acquired pulmonary vein stenosis 1

Critical Management Point

PAH-specific therapies (endothelin receptor antagonists, phosphodiesterase-5 inhibitors, prostacyclins) are contraindicated in Group 2 PH because they may precipitate life-threatening pulmonary edema by increasing pulmonary blood flow without reducing left-sided pressures. 1

---

Group 3: Pulmonary Hypertension Due to Lung Diseases and/or Hypoxia

Hemodynamic Profile

Pre-capillary pattern: mean PAP ≥25 mmHg, PAWP ≤15 mmHg. 1

Pathophysiology

Chronic hypoxia causes pulmonary vasoconstriction and vascular remodeling. 1 While PH secondary to chronic lung disease is common, severe elevation (mean PAP ≥35 mmHg) is relatively rare. 1

Etiologies

• Chronic obstructive pulmonary disease (COPD): Most common lung disease associated with PH 1
• Interstitial lung disease: Including idiopathic pulmonary fibrosis 1
• Sleep-disordered breathing: Obstructive sleep apnea and obesity-hypoventilation syndrome 1
• Alveolar hypoventilation disorders 1
• Chronic exposure to high altitude 1
• Developmental lung diseases 1

Management Principle

Treatment focuses on the underlying lung disease; PAH-specific therapies are not recommended. 2

---

Group 4: Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and Other PA Obstructions

Hemodynamic Profile

Pre-capillary pattern: mean PAP ≥25 mmHg, PAWP ≤15 mmHg. 1

Pathophysiology

CTEPH results from organized thrombotic material obstructing pulmonary arteries, producing mechanical obstruction and secondary small-vessel arteriopathy. 1

Etiologies

• Chronic thromboembolic pulmonary hypertension (proximal or distal arterial obstruction) 1
• Other PA obstructions:
  • Pulmonary angiosarcoma and other intravascular tumors 1
  • Pulmonary artery arteritis 1
  • Congenital pulmonary artery stenoses 1
  • Parasites (hydatid disease) 1

Management

Pulmonary thromboendarterectomy is the treatment of choice for eligible patients; balloon pulmonary angioplasty or medical therapy can be considered for inoperable cases. 2

---

Group 5: Pulmonary Hypertension with Unclear and/or Multifactorial Mechanisms

Hemodynamic Profile

May be pre-capillary or post-capillary depending on the specific condition. 1

Pathophysiology

These conditions do not fit clearly into Groups 1–4 and involve complex or incompletely understood mechanisms. 1

Etiologies

Hematologic disorders:

• Chronic hemolytic anemia (sickle cell disease, thalassemia, hereditary spherocytosis) 1
• Myeloproliferative disorders 1
• Post-splenectomy states 1

Note: Chronic hemolytic anemia was moved from Group 1 to Group 5 because it differs significantly from classic PAH—it lacks plexiform lesions, shows low PVR with high cardiac output, and does not respond to PAH-specific therapies. 1

Systemic disorders:

• Sarcoidosis 1
• Pulmonary Langerhans cell histiocytosis 1
• Lymphangioleiomyomatosis 1
• Neurofibromatosis 1

Metabolic disorders:

• Glycogen storage diseases 1
• Gaucher disease 1
• Thyroid disorders 1

Miscellaneous:

• Pulmonary tumoral thrombotic microangiopathy 1
• Fibrosing mediastinitis causing vascular compression 1
• Chronic renal failure (with or without dialysis) 1
• Segmental pulmonary hypertension (discrete lung areas perfused by aorto-pulmonary collaterals in congenital heart disease) 1

---

Diagnostic Algorithm

Right heart catheterization is mandatory to confirm the diagnosis of pulmonary hypertension, classify its hemodynamic type, and guide treatment decisions; echocardiography alone is insufficient. 1, 6

Key Measurements Obtained by RHC:

• Mean pulmonary artery pressure (confirms PH diagnosis) 6
• Pulmonary artery wedge pressure (distinguishes pre-capillary from post-capillary PH) 6
• Cardiac output via thermodilution (required for PVR calculation) 6
• Right atrial pressure (assesses right heart dysfunction and prognosis) 6
• Calculated PVR and transpulmonary gradient 6

Technical Considerations:

• RHC should be performed at expert centers with morbidity ~1.1% and mortality ~0.055% 6
• Pressures must be recorded at end-expiration without breath-holding 6
• Zero referencing at mid-thoracic line is essential 6
• Spontaneous variability can reach ±20 mmHg; multiple measurements are necessary 6

---

Clinical Pitfalls

• Do not rely on echocardiography alone to make treatment decisions; Doppler-derived pressure estimates may be inaccurate in individual patients. 1, 6
• Do not use PAH-specific therapies empirically in Group 2 PH; they can cause life-threatening pulmonary edema. 1
• Do not use calcium channel blockers without documented vasoreactivity testing; they are harmful in non-responders. 6
• Recognize that normal serum creatinine does not exclude significant renal involvement in conditions like hemolytic uremic syndrome that may mimic or coexist with PH. 7
• Maintain epidemiologic suspicion for rare causes such as hantavirus pulmonary syndrome in previously healthy adults with acute ARDS-like presentation and appropriate exposure history. 7